Muscle Health Revolution: The Next Trillion-Dollar CPG Opportunity

As one form of cultural capital is democratized, “the elite” promptly establish a new (less accessible) social asset. Therefore, what could it mean across the CPG landscape after GLP-1s made thinness no longer a pursuit of rarity? And while I recently shared a short-form content piece on this topic, it was not nearly enough time to properly assess massive opportunities emerging from this social phenomenon. Either way, my hope is to expand (while also simplifying) a messy sociology and economics intersection that blends elements of the “leisure class theory” and the concept of social distinction (along with) my own first principles thinking. The result? Optimistically, you’ll clearly see the beginning of an enormous (potentially multi-decade long) structural realignment of consumer demand, as this new “Age of Ozempic” era is facilitating a "measuring stick" shift (with thinness commoditized) and strength (defined by lean muscle and metabolic health) elevating into the ultimate social status. But consumer surveys still show most Americans are interested in losing weight. So, why are “the elite” changing the social distinction game…even as the previous one still feels mostly inaccessible to a broader population? Whether analyzing over a 100 million annual BMI classifications, taking notice of recent CDC data involving adult obesity rates, or noticing that calories consumed per capita is declining…it appears obesity has peaked in the United States. However, that societal trend alone isn’t the culprit. Instead, its centers around how GLP-1 medications have become this sort of "social technology," rapidly moving thinness from a result of extreme discipline (and/or maybe rare genetics) to a broadly accessible pharmaceutical outcome. So, because GLP-1s often cause significant muscle loss, maintaining a "strong" physique now requires a level of investment that the drugs alone cannot provide. Accordingly, muscle mass serves as a signal of disposable income, time, and agency over one's schedule, as it requires resistance training and specific nutritional regimens that are harder to sustain than medication alone. Hence, the new social distinction isn’t just about weight, but the biological quality of the body…with strength now framed as a “critical measure of health.” And the CPG industry has also been strategically repositioning itself to sell this new social distinction. And that’s obviously the sector lens I primarily utilized when making the comment about “then you probably need to learn more about what I’ve dubbed the foundational triad of muscle health” within my beforementioned short-form content. Although (in all honesty) just recognizing protein, creatine, and HMB could (very) likely grow their relevance (and inclusion) even further within the various categorical intersections across packaged foods, beverages, and dietary supplements…probably isn’t a compelling enough insight, right? Nonetheless, what happens when a sizable share of the CPG industry strategically repositions themselves to (more obviously) sell this new social distinction? It appears this new “Age of Ozempic” era is facilitating a "measuring stick" shift (with thinness commoditized) and strength (defined by lean muscle and metabolic health) elevating into the ultimate social status, which should trigger a multi-decade “muscle health revolution” (effectively putting consumers in a trillion-dollar productized chokehold)!